TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).

Inclusion Criteria:

• Confirmed diagnosis of multiple myeloma
• Evidence of relapsed or refractory disease

Exclusion Criteria:

• Intracranial disease or epidural disease
• Clinically significant cardiac disease
• Diabetes mellitus